We're pleased to announce that Pharmica has joined ProPharma Group.

Together we are forming the world's leading provider of regulatory, clinical, and compliance services supporting clients throughout the full product lifecycle. Learn about our expanded services.

New Strategies Generate Optimism for Targeting “Undruggable” KRAS

Vassiliki Papadimitrakopoulou, MD After 30 years of frustration, investigators are starting to make headway in their quest to develop therapies that counteract oncogenic mutations in the KRAS gene, a high-priority target in precision medicine that has long been deemed “undruggable.” 1-3 The discovery of binding pockets on a mutant […] Click here to view original[…]